Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis 3Q

Pharmaceutical sales in the quarter were $7.2 billion (+8%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis 3Q

3Q Revenues: $11.1 billion (+3%)

3Q Earnings: $2.1 billion (+1%)

YTD Revenues: $31.3 billion (flat)

YTD Earnings: $6.1 billion (-8%)

Comments: Pharmaceutical sales in the quarter were $7.2 billion (+8%). Diovan sales were $4.4 billion (+5% in local currencies), driven by expansion in Japan, which accounts for approximately 20% of sales. Exforge sales were $475 million (+81% lc). Tekturna/Rasilez sales were $202 million (+114% lc). Gleevec/Glivec sales were $2.9 billion (+12% lc). Zometa sales were $1.1 billion(+9% lc). Femara sales were $925 million (+16% lc). Exjade sales were $469 million (+30% lc). Sandoz revenue was $1.9 billion (-3%). Vaccines and Diagnostics sales were down 18% to $543 million, due to lower sales of H5N1 (avian flu) pandemic vaccines in 2009.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters